IIFL Capital starts coverage on India's Cohance with 'buy'

Cohance Lifesciences

29/08/2025 05:14

** IIFL Capital initiates coverage on contract research and drug manufacturing firm Cohance Lifesciences COHA.NS with "buy" and PT of 1,140 rupees

** Brokerage says COHA's acquisitions of drugmakers NJ Bio and Sapala strengthen its position in the fast-growing market of antibody drug conjugates (ADC), also known as "guided missile drugs" as they directly target cancer cells, minimizing damage to healthy cells

** Jefferies' PT highest among six analysts tracking COHA - data compiled by LSEG

** Revenue contribution from COHA'S niche tech, which includes these new molecules, is expected to double from 17% in FY25 to over 35% by FY30 - Jefferies

** Avg rating of analysts on COHA at "strong buy"; median PT is 1,235 rupees - data compiled by LSEG

** YTD, COHA stock down 23.4%

 (Reporting by Kashish Tandon in Bengaluru)

 ((Kashish.tandon@thomsonreuters.com))